Comparison of Remogliflozin and Canagliflozin as Add-On Therapy in Indian Uncontrolled T2DM Subject

被引：0
|
作者：
Shankar, Anand
机构：
来源：
DIABETES | 2020年 / 69卷
关键词：
D O I：
10.2337/db20-1114-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1114-P
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Efficacy and Safety of Saxagliptin Add-on to Metformin Compared with Acarbose Add-on to Metformin in Patients with Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled with Metformin Monotherapy
    Du, Jin
    Liang, Li
    Fang, Hui
    Xu, Fengmei
    Li, Wei
    Shen, Liya
    Mu, Yiming
    DIABETES, 2016, 65 : A293 - A293
  • [32] ACHIEVEMENT OF GLYCAEMIC TARGETS WITH CANAGLIFLOZIN IN TRIPLE THERAPY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)
    Diels, J.
    Schubert, A.
    Hamilton, G.
    Canovatchel, W.
    VALUE IN HEALTH, 2015, 18 (07) : A598 - A598
  • [33] Empagliflozin as Add-On to Metformin for 24 Weeks Improves Glycemic Control in Patients With Type 2 Diabetes (T2DM)
    Haering, Hans-Ulrich
    Merker, Ludwig
    Seewaldt-Becker, Elke
    Weimer, Marc
    Meinicke, Thomas
    Broedl, Uli C.
    Woerle, Hans J.
    DIABETES, 2013, 62 : A282 - A282
  • [34] Target Achievement and Quality Measure (QM) Attainment with Titrated Canagliflozin (CANA) in Patients with Type 2 Diabetes Mellitus (T2DM) as Add-on to Metformin (MET) plus Sitagliptin (SITA)
    Seufert, Jochen
    Aggarwal, Naresh
    Bailey, Robert
    Cao, Anjun
    Fung, Albert
    Pfeifer, Michael
    Alba, Maria
    Rodbard, Helena W.
    DIABETES, 2016, 65 : A308 - A308
  • [35] Empagliflozin (EMPA) for ≥76 Weeks as Add-on to Pioglitazone With or Without Metformin in Patients with Type 2 Diabetes (T2DM)
    Kovacs, Christopher S.
    Seshiah, Veeraswamy
    Merker, Ludwig
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Stella, Peter
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES, 2014, 63 : A273 - A273
  • [36] Empagliflozin as Add-On to Pioglitazone With or Without Metformin Improves Glycemic Control in Patients With Type 2 Diabetes (T2DM)
    Kovacs, Christopher
    Seshiah, Veeraswamy
    Swallow, Ros
    Jones, Russell
    Rattunde, Henning
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES, 2013, 62 : A291 - A291
  • [37] Empagliflozin (EMPA) for ≥76 Weeks As Add-on to Pioglitazone with or without Metformin in Patients with Type 2 Diabetes (T2DM)
    Kovacs, Christopher Simon
    Seshiah, Veeraswamy
    Merker, Ludwig
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Stella, Peter
    Woerle, Hans-Juergen
    Broedl, Uli C.
    ENDOCRINE REVIEWS, 2014, 35 (03)
  • [38] Efficacy and Safety of Colesevelam HCl (COL) as an Add-On to Pioglitazone (PIO) for Type 2 Diabetes Mellitus (T2DM)
    Ford, Daniel M.
    Baz-Hecht, Merav
    Said, Nabil A.
    Tao, Ben
    Truitt, Kenneth E.
    Chou, Hubert S.
    DIABETES, 2013, 62 : A273 - A273
  • [39] Designing a new therapy for T2DM
    Greenhill, Claire
    NATURE REVIEWS ENDOCRINOLOGY, 2019, 15 (12) : 684 - 684
  • [40] Combination Therapy of Canagliflozin and Teneligliptin in Japanese Patients with T2DM: Results from Phase 3 Studies
    Kaku, Kohei
    Kadowaki, Takashi
    Inagaki, Nobuya
    Kondo, Kazuoki
    Nishimura, Kenichi
    Kaneko, Genki
    Maruyama, Nobuko
    Nakanishi, Nobuhiro
    Iijima, Hiroaki
    Watanabe, Yumi
    Goda, Maki
    DIABETES, 2017, 66 : A319 - A319
12345